Publication date: Jul 01, 2026
Organising pneumonia is an interstitial lung disease linked to infections and other conditions. Cryptogenic organising pneumonia is a rarer, idiopathic form. Organising pneumonia has become one of the most frequent respiratory complications following severe acute respiratory syndrome coronavirus 2 pneumonia. Standard treatment involves the use of glucocorticoids. The objective of the study is to determine the optimal dosage of oral corticosteroids for the treatment of this disease. Randomised, open-label, assessor-blinded, parallel-group, single-centre, noninferiority clinical trial with an active control group comparing two oral prednisone regimens. The control group received prednisone 0. 75 mg.kg.day for 4 weeks; 0. 5 mg.kg.day for 4 weeks; 20 mg.day for 4 weeks; 10 mg.day for 6 weeks; or 5 mg.day for 6 weeks (total treatment duration 6 months) and the experimental group prednisone 0. 5 mg.kg.day for 3 weeks; 20 mg.day for 3 weeks; 15 mg.day for 2 weeks; 10 mg.day for 2 weeks; and 5 mg.day for 2 weeks (total treatment duration 3 months). Visits were carried out at baseline and at 3, 6 and 12 months, recording clinical history, physical examination, pulmonary function tests and chest computed tomography. The primary outcome was noninferiority with a margin of 10% in diffusing capacity of the lung for carbon monoxide (D ) at 6 months. 79 patients were randomised according to intention-to-treat group, 40 to the experimental group and 39 to the control group. Mean+/-sd baseline D was 59. 3+/-16. 7% in the experimental group and 55. 5+/-16. 5% in the control group, with mean improvements at 6 months of 11. 7% (95% CI 7. 18-16. 17%) and 12. 8% (95% CI 8. 57-17. 11%) respectively. The difference between groups at 6 months was 1. 23% (95% CI -5. 13-7. 59%), the experimental regimen being noninferior to the control group with the margin of 10%. Patients in the experimental group had fewer than half as many adverse effects as controls: nine (23%) versus 22 (56%) (p=0. 0027). Treatment with oral corticosteroids lasting 3 months (initial dose of prednisone 0. 5 mg.kg.day) may be recommended in patients with post-COVID organising pneumonia.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | interstitial lung disease |
| disease | MESH | infections |
| disease | MESH | severe acute respiratory syndrome |
| disease | MESH | pneumonia |
| drug | DRUGBANK | Prednisone |
| disease | MESH | pulmonary function |
| drug | DRUGBANK | Carbon monoxide |